Chemotherapy‑induced fatal hepatitis B virus reactivation in a small‑cell lung cancer patient

Qin,Lei; Wang,Fang; Zou,Bing‑Wen; Ding,Zhen‑Yu

doi:10.3892/mco.2016.989

Chemotherapy‑induced fatal hepatitis B virus reactivation in a small‑cell lung cancer patient

Authors:
- Lei Qin
- Fang Wang
- Bing‑Wen Zou
- Zhen‑Yu Ding
View Affiliations

Affiliations: Division of Head and Neck Cancer, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, Division of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: August 11, 2016 https://doi.org/10.3892/mco.2016.989
Pages: 382-384
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis B virus (HBV) reactivation during chemotherapy is a major concern and is widely reported, particularly in association with hematological malignancies and lymphomas. While lung cancer ranks first in incidence and mortality worldwide, HBV reactivation has been largely overlooked in this disease. As regards small‑cell lung cancer (SCLC), HBV reactivation has rarely been reported. We herein report the case of a hepatitis B surface antigen‑seropositive SCLC patient in whom HBV was reactivated during the course of chemotherapy, despite preemptive use of lamivudine. The patient developed fulminant viral hepatitis and succumbed to liver failure. The aim of this report was to highlight the major but overlooked issue of HBV reactivation in SCLC, and suggest that agents more potent than lamivudine may be more efficacious in high‑risk patients.

View Figures

View References

1	Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
2	Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol. 62:299–307. 2000. View Article : Google Scholar : PubMed/NCBI
3	Mandala M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R and Roila F: Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol. 87:12–27. 2013. View Article : Google Scholar : PubMed/NCBI
4	Yeo W and Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lin GN, Peng JW, Xiao JJ, Liu DY and Xia ZJ: Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: The efficacy of preemptive lamivudine and identification of risk factors. Med Oncol. 31:1192014. View Article : Google Scholar : PubMed/NCBI
7	Liaw YF and Chu CM: Hepatitis B virus infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hoofnagle JH, Doo E, Liang TJ, Fleischer R and Lok AS: Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 45:1056–1075. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lok AS and McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, et al: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 22:927–934. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R and Liang R: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 125:1742–1749. 2003. View Article : Google Scholar : PubMed/NCBI
12	Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology. 47:844–853. 2008. View Article : Google Scholar : PubMed/NCBI
13	Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, et al: A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 127:705–712. 2011. View Article : Google Scholar : PubMed/NCBI
14	Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, et al: Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA. 312:2521–2530. 2014. View Article : Google Scholar : PubMed/NCBI